ALKERMES | ALKS - 资产

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 7.02B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	资产	更改		日
AbbVie	USD 136.46B		2.5B	2026-03
Acadia Pharmaceuticals	USD 1.61B		41.04M	2026-03
ALKERMES	USD 4.26B		1.77B	2026-03
Amgen	USD 92.5B		1.92B	2026-03
Biogen	USD 29.48B		43.6M	2026-03
BioMarin Pharmaceutical	USD 8.59B		996.99M	2026-03
Bristol-Myers Squibb	USD 86.48B		3.56B	2026-03
Coherus Biosciences	USD 258.34M		258.18M	2025-12
Eli Lilly	USD 116.58B		4.1B	2026-03
Gilead Sciences	USD 56.28B		2.74B	2026-03
Heron Therapeutics	USD 246.22M		9.66M	2026-03
Ionis Pharmaceuticals	USD 3.45B		74M	2026-03
J&J	USD 200.89B		1.68B	2026-03
Malin Corporation	EUR 198.5M		70.1M	2024-12
Merck	USD 128.68B		8.18B	2026-03
Minerva Neurosciences	USD 97.97M		69.88M	2025-12
Nektar Therapeutics	USD 280.41M		20.94M	2025-12
Neurocrine Biosciences	USD 4.91B		274.7M	2026-03
Otsuka Holdings	JPY 4.21T		11.63B	2026-03
Ovoca Bio	EUR 1.66M		9.75M	2025-06
Pfizer	USD 207.62B		542M	2026-03
Regeneron Pharmaceuticals	USD 40.87B		310.1M	2026-03
Vertex Pharmaceuticals	USD 26.48B		841.4M	2026-03